venetoclax plus ibrutinib combo shows potential in relapsed/refractory mcl
Published 4 years ago • 91 plays • Length 0:47Download video MP4
Download video MP3
Similar videos
-
1:24
dr. goy on preliminary data with ibrutinib/venetoclax in relapsed/refractory mcl
-
6:11
ibrutinib beats temsirolimus in relapsed/refractory mcl
-
1:27
real-world data for ibrutinib in relapsed/refractory mcl
-
1:27
dr. rule on the combination of venetoclax and ibrutinib in mcl
-
2:48
using ibrutinib in relapsed/refractory mzl
-
1:22
dr. kaplan on the combination of ibrutinib and venetoclax in mcl
-
1:09
dr. goy discusses ibrutinib with venetoclax in mcl
-
1:08
dr. tam on the toxicity of ibrutinib plus venetoclax in mcl
-
1:56
dr. tam on the combination of ibrutinib plus venetoclax in mantle cell lymphoma
-
1:27
dr. ritchie on immunological response to venetoclax/ibrutinib in r/r mcl
-
3:18
sympatico: safety and efficacy of ibrutinib plus venetoclax for r/r mcl
-
1:51
long-term results of ibrutinib/umbralisib show efficacy in cll and mcl
-
1:28
ibrutinib and venetoclax: a powerful combination in frontline and relapsed cll
-
1:08
dr. tam on the toxicities of ibrutinib plus venetoclax in mcl
-
2:06
the role of venetoclax in r/r mcl & options for patients who progress on venetoclax
-
3:06
durable responses to ibrutinib and venetoclax in r/r mcl: 3-year aim update
-
1:30
oasis trial update: ibrutinib, venetoclax plus obinutuzumab in newly diagnosed mcl
-
1:09
dr. ritchie on the immunologic impact of long-term venetoclax/ibrutinib in r/r mcl
-
5:18
venetoclax’s role in relapsed/refractory cll